Salarius Pharmaceuticals, Inc. financial data

Symbol
SLRX on Nasdaq
Industry
Pharmaceutical Preparations
Location
2450 Holcombe Blvd, Suite J 608, Houston, TX
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Flex Pharma, Inc. (to 7/22/2019)
Latest financial report
10-Q - Q2 2024 - Aug 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 34.7 % -8.42%
Return On Equity -149 % +49.2%
Return On Assets -110 % +48%
Operating Margin -3K % -2128%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.44M shares -60.4%
Common Stock, Shares, Outstanding 641K shares -80.9%
Entity Public Float 4.92M USD -57.8%
Common Stock, Value, Issued 64 USD -80.9%
Weighted Average Number of Shares Outstanding, Basic 600K shares +77.3%
Weighted Average Number of Shares Outstanding, Diluted 600K shares +77.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 1.55M USD -89.3%
General and Administrative Expense 5.19M USD -25.2%
Operating Income (Loss) -6.74M USD +77.8%
Net Income (Loss) Attributable to Parent -6.46M USD +78.5%
Earnings Per Share, Basic 7.06 USD/shares +79.3%
Earnings Per Share, Diluted 7.06 USD/shares +79.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.27M USD -71.6%
Other Assets, Current 152K USD -13.1%
Assets, Current 3.51M USD -70.6%
Property, Plant and Equipment, Net 4.19K USD -77.9%
Goodwill 0 USD -100%
Other Assets, Noncurrent 39.9K USD -59.7%
Assets 3.55M USD -70.5%
Accounts Payable, Current 643K USD -71.9%
Liabilities 1.18M USD -67.6%
Retained Earnings (Accumulated Deficit) -79.5M USD -8.85%
Stockholders' Equity Attributable to Parent 2.38M USD -71.8%
Liabilities and Equity 3.55M USD -70.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.35M USD +57.3%
Net Cash Provided by (Used in) Financing Activities -173K USD -151%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 641K shares -80.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.53M USD +46.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3.27M USD -71.6%
Interest Paid, Excluding Capitalized Interest, Operating Activities 4.02K USD
Deferred Tax Assets, Valuation Allowance 15.9M USD +21.9%
Deferred Tax Assets, Gross 15.9M USD +21.9%
Deferred Tax Assets, Operating Loss Carryforwards 6.16M USD +57.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 81.9M USD +0.52%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 1.11K USD -33.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%